$STVN: are oral GLP-1s really a death blow? | Aurelian Research's Leo Trudel

Episode Summary

Executive Summary: The episode examines Stevanato Group (STVN), a glass containment and delivery systems supplier to large pharma, as a misunderstood compounder. Leo Trudell argues the market is overreacting to GLP-1 oral-drug concerns and underappreciating three catalysts: persistent biologics demand, a shift toward higher-margin high-value solutions, and a capex cycle turning into free cash flow. Andrew is more cautious, emphasizing valuation, demand uncertainty, and the risk that market fears may prove right.

Main Topics: What Stevanato Group Does and Why It Matters (Priority: 5/5): Stevanato makes glass vials, cartridges, syringes, and related containment/delivery systems used by major pharma companies for injectables, especially biologics and GLP-1 drugs. GLP-1 Oral Versus Injectable Debate (Priority: 5/5): The central controversy is whether oral GLP-1 drugs will materially reduce demand for injectable formats and leave Stevanato overbuilt after heavy capital spending. Margin Expansion and Product Mix Shift (Priority: 5/5): Leo argues a growing share of revenue is coming from higher-value, higher-margin biologics-related solutions, which should expand EBITDA margins without aggressive cost cutting. CapEx Cycle Turning Into Free Cash Flow (Priority: 4/5): The company spent heavily on new plants to meet demand, but that spend should taper, allowing free cash flow to improve as capacity comes online and utilization rises. Regulatory Spec-In and Customer Lock-In (Priority: 4/5): The business benefits from being 'spec-in' to drug formulations, making switching costly and slow for customers; this creates long product cycles and pricing power. Capital Allocation and Future Uses of Cash (Priority: 3/5): Once CapEx moderates, the discussion shifts to how Stevanato may deploy cash through buybacks, dividends, and bolt-on acquisitions rather than transformative M&A. Valuation and Investment Style Fit (Priority: 3/5): Andrew agrees the business is high quality but says the valuation and lack of a distress/event angle make it less attractive for his style, even if it can compound over time.

Key Arguments: Stevanato is not just a GLP-1 story; about half of the business is tied to broader biologics growth, which is still expanding strongly. Leo believes oral GLP-1s will not fully replace injectables because efficacy is lower and adherence is harder, especially for severe patients and older patients. The company’s mix shift toward high-value solutions should drive EBITDA margin expansion even without cost cuts. Heavy capex was necessary to meet demand across biologics, and the cycle is now moving toward free cash flow generation. The market is assigning too much downside to GLP-1 oral competition, causing an exaggerated stock decline relative to likely fundamentals. The spec-in regulatory model creates long-duration customer lock-in and makes switching difficult, supporting a durable moat. Andrew argues the stock is a quality compounder but not clearly mispriced enough to offer a strong risk-adjusted edge at current valuation. Andrew warns that management forecasts and customer visibility can disappoint, so the narrative may be less stable than the market assumes. Management may favor buybacks and selective acquisitions once cash generation improves, but Andrew notes industry consolidation remains difficult because customers need multiple qualified suppliers.

Data Points: Ticker: STVN - Stevanato Group’s U.S.-traded ticker Customer concentration: 23 of the 24 largest pharma customers - Leo highlighted the breadth of the company’s customer base Stock decline from peak: ~50% - Andrew noted the stock is down roughly half from its all-time high amid GLP-1 oral concerns Historical valuation: ~20x EBITDA - Leo said the stock used to trade around this level before the recent rerating Current valuation range: ~11-13x EBITDA - Andrew estimated the current forward/backward EBITDA multiple Free cash flow conversion: ~50% of EBITDA - Leo said the company can convert about half of EBITDA into actual cash on a good basis Revenue mix growth: ~15-18% growth for one half; ~2% for the other half - Leo described a bifurcated business with higher-growth, higher-margin biologics solutions Gross margin profile: High-value solutions have about 2x the gross margin - Leo said the higher-value segment carries roughly double the gross margin of containment products EBITDA margin expansion: ~1.2% margin expansion contribution - Leo said mix shift alone could drive about 1.2 percentage points of EBITDA margin expansion EBITDA margin outlook: 25% to 30-32% over five years - Leo projected expansion as the mix shifts and CapEx normalizes CapEx spend: 100s of millions of dollars - Leo referenced major investments in new plants in the U.S. and Italy GLP-1 addressable market penetration: ~10% treated - Leo cited low penetration as a reason the market can still grow even with oral competition GLP-1 growth in FY25: Over 20% - Andrew referenced company commentary that GLP-1 growth remained strong in FY25 Expected GLP-1 growth with oral competition: Mid-teens - Andrew referenced guidance/expectations that growth could still remain in the mid-teens Dividend yield: ~0.4% - Leo said the dividend is low and mainly serves to pay the founding family AI workflow: Transcripts and proxies summarized in minutes - Both speakers discussed using AI to process company filings and transcript history faster

Pivotal Quotes: "I think this is a great long-term compounder to have in your portfolio." — Leo Trudell: His core bullish thesis on Stevanato despite GLP-1 oral-drug concerns "The market is just too stressed on GLP-1." — Leo Trudell: Leo’s explanation for why the stock has rerated too sharply "For me, that's just like historically, it's not where I've had the most success." — Andrew Walker: Andrew explaining why he would not buy STVN despite liking the business

Implications: The debate hinges on whether oral GLP-1s materially weaken long-term demand or simply slow growth while biologics and mix shift keep earnings compounding. If Leo is right, the stock is undervalued; if Andrew is right, valuation and execution risk justify caution.